Kinfo
Axogen Inc. logo

Axogen Inc.

AXGNNASDAQHealthcare·US · USD
$48.19
+1.76 (+3.79%)
Prices as of August 10, 2026 · market closed

Price

Key statistics

Valuation
Market cap2.59B USD
Enterprise value2.40B USD
Trailing P/E-141.74
Forward P/E67.91
PEG ratio0.35
Price / sales10.05
Price / book9.83
Profitability
Gross margin72.67%
Operating margin-3.09%
Profit margin-13.36%
Return on assets-3.15%
Return on equity-18.21%
Income (TTM)
Revenue251.17M USD
Gross profit187.26M USD
EBITDA826.00K USD
Net income-33.55M USD
Diluted EPS-$0.67
Rev. growth (YoY)23.10%
Balance sheet
Total cash111.41M USD
Total debt20.07M USD
Debt / equity7.83
Current ratio6.60
Book value / share$4.78
Cash flow (TTM)
Operating cash flow15.05M USD
Levered free cash flow18.23M USD
Shares & price
Shares outstanding53.18M
Float52.06M
Held by institutions98.57%
Beta1.14
50-day MA$42.42
200-day MA$34.80
52-week high$48.59
52-week low$13.64
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Recent payments
  • 2010-01-27$1.00
Earnings (EPS)
DateEst.ActualSurprise2026-07-290.120.12+0.00%2026-06-11-0.33-0.09+72.73%2026-04-280.070.07+0.00%2026-03-170.420.65+54.76%2026-02-240.100.07−30.00%
About Axogen Inc.

Axogen Inc. is a leading developer and marketer of innovative surgical solutions for peripheral nerve regeneration and repair. The company specializes in biologically active technologies, including the Avance Nerve Graft, an off-the-shelf processed human nerve allograft that bridges severed peripheral nerves without requiring a second surgical site. Its portfolio also features the AxoGuard Nerve Connector and AxoGuard Nerve Protector, porcine submucosa extracellular matrix products that enable tensionless nerve repairs and protection; the AxoGuard Nerve Cap for nerve end treatment; and the Avive Soft Tissue Membrane for soft tissue management. Additionally, Axogen offers the AxoTouch Two-Point Discriminator, a tool for assessing skin innervation density. These products serve hand surgeons, reconstructive plastic surgeons, oral and maxillofacial surgeons, and other specialists treating nerve injuries across the body. Axogen Inc. provides these solutions to healthcare providers in the United States, Canada, Europe, South Korea, and other international markets, aiming to restore nerve function, sensation, and patient quality of life. Headquartered in Alachua, Florida, the company focuses on advancing peripheral nerve repair as a standard of care in surgical practice.

Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Michael D. Dale
Employees
622
Headquarters
Alachua, FL, United States

Frequently asked questions about Axogen Inc.